Breast cancer treatment is a life-saver but also can have side effects, including some related to shoulder pain. It is good to start doing the exercises as soon as the doctor recommends it. After that, a regular tune-up with a physical therapist can help.
The Food and Drug Administration has granted an accelerated approval to the frontline combination of Tecentriq (atezolizumab) plus Abraxane (nab-paclitaxel) for patients with unresectable locally advanced or metastatic PD-L1–positive triple-negative breast cancer (TNBC).
From artificial intelligence to a surprise FDA resignation, check out this week’s quick overview of what is making headlines in the cancer space.
Time-limited treatment could be the new wave of research in the treatment of chronic lymphocytic leukemia (CLL), according to Nicole Lamanna, M.D.
The oral blood thinner Xarelto (rivaroxaban) significantly reduced blood clots for high-risk patients with cancer being treated in the outpatient setting, according to results from the CASSINI trial.
We've got a sneak peek at what’s inside our Winter 2019 issue.
Does your cancer diagnosis grow your patience and ability to live with change and cope with the unknown? Absolutely.
An expert describes how far the field has come, with two treatments approved and more in the works.
Sameek Roychowdhury, M.D., Ph.D., discusses the importance of molecular testing to determine treatment options for cholangiocarcinoma.
Alex Trebek, the long-time host of the popular game show "Jeopardy!", announced that he received a diagnosis of stage 4 pancreatic cancer.
Recovering from cancer and its aftermath is like grief; always changing, undulating and rippling like a tide.
Frontline use of Bavencio (avelumab) plus Inlyta (axitinib) significantly improved progression-free survival compared with the standard of care in patients with advanced renal cell carcinoma.
Partnerships to Coincide with NCAA Basketball Tournaments
This survivor details her journey with breast implants following a modified radical mastectomy.
The U.S. Food and Drug Administration (FDA) will give a priority review to the experimental targeted drug fedratinib as a potential treatment for the blood cancer myelofibrosis.
Learn how the pain through the trauma of cancer can transform in positive ways.
CURE® sponsors a fun and free introduction to this playful practice for health and healing.
In order to help others, this survivor and author must "bare all" to get his message out.
Association of Community Cancer Centers' survey finds heavy workloads and workflow inefficiencies are top concerns.
Can medical grade marijuana and CBD help with residual pain after a cancer diagnosis, and why is it so scary for a survivor to ask for it?
The U.S. Food and Drug Administration has expanded the approval of Cinvanti injectable emulsion to include a two-minute intravenous use for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.
How do you trust your body when it has genetics that could give you cancer? Who do you turn to for support?
From radioactive remains to entertainment news, check out this week’s quick overview of what is making headlines in the cancer space.
Here are the top 5 CURE stories for February 2019.
The one-day agenda hosts faculty and panels discussing breast cancer treatments and their side effects, genetics, survivorship, and more.
What happens when the trick goes wrong?
Why use one term over the other? It's not about exclusion, but rather inclusion and reaching all at risk for this disease-- which happens to be everyone.
The FDA has approved subcutaneous use of Herceptin and Herceptin Hylecta in combination with chemotherapy for the treatment of select patients with HER2-positive early breast cancer.
A liquid biopsy test detected all of the guideline-recommended biomarkers in newly diagnosed patients with metastatic non-small cell lung cancer at a similar rate but faster than tissue genotyping.
The Oncologic Drugs Advisory Committee (ODAC) voted 8 to 5 recommending the FDA delay approval of selinexor for the treatment of patients with penta-refractory multiple myeloma until further trial data are available.
